ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00645775
Recruitment Status : Completed
First Posted : March 28, 2008
Last Update Posted : March 28, 2008
Sponsor:
Collaborator:
University of Yaounde
Information provided by:
Gateway Health Alliance

March 25, 2008
March 28, 2008
March 28, 2008
November 2006
March 2007   (Final data collection date for primary outcome measure)
Weight change [ Time Frame: 10 weeks ]
Same as current
No Changes Posted
Change in blood lipids and hormone levels [ Time Frame: 10 weeks ]
Same as current
Not Provided
Not Provided
 
Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome
The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.
The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants.

The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis.

Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.

Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Metabolic Syndrome
  • Obesity
  • Dyslipidemia
Dietary Supplement: IGOB131
Comparison of 250 mg per day of Irvingia gabonensis to placebo
Placebo Comparator: 1
Compare active to placebo
Intervention: Dietary Supplement: IGOB131
Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids Health Dis. 2009 Mar 2;8:7. doi: 10.1186/1476-511X-8-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
102
Same as current
April 2007
March 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI>26

Exclusion Criteria:

  • Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers
Sexes Eligible for Study: All
19 Years to 50 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Cameroon
 
 
NCT00645775
GHAIGOB131CT
Yes
Not Provided
Not Provided
Pr. Julius Oben, CSO, Gateway Health Alliances
Gateway Health Alliance
University of Yaounde
Study Director: Julius E Oben, PhD Gateway Health Alliances / University of Yaounde
Gateway Health Alliance
August 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP